SV2009003421A - Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas - Google Patents

Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas

Info

Publication number
SV2009003421A
SV2009003421A SV2009003421A SV2009003421A SV2009003421A SV 2009003421 A SV2009003421 A SV 2009003421A SV 2009003421 A SV2009003421 A SV 2009003421A SV 2009003421 A SV2009003421 A SV 2009003421A SV 2009003421 A SV2009003421 A SV 2009003421A
Authority
SV
El Salvador
Prior art keywords
microparticles
release composition
prolonged release
somatostatin derivative
somatostatin
Prior art date
Application number
SV2009003421A
Other languages
English (en)
Inventor
Olivier Lambert
Marc Riemenschnitter
Vitomir Vucenovic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2009003421(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2009003421A publication Critical patent/SV2009003421A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A MICROPARTÍCULAS MEJORADAS QUE COMPRENDEN UN ANÁLOGO DE SOMATOSTATINA, A UN PROCESO PARA LA ELABORACIÓN DE ESTAS MICROPARTÍCULAS, Y A COMPOSICIONES FARMACÉUTICAS QUE LAS COMPRENDEN
SV2009003421A 2007-05-24 2009-11-24 Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas SV2009003421A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07108796 2007-05-24

Publications (1)

Publication Number Publication Date
SV2009003421A true SV2009003421A (es) 2010-05-21

Family

ID=38222465

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003421A SV2009003421A (es) 2007-05-24 2009-11-24 Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas

Country Status (42)

Country Link
US (2) US20100178344A1 (es)
EP (2) EP2164473B1 (es)
JP (1) JP5507447B2 (es)
KR (2) KR101930588B1 (es)
CN (1) CN101677965B (es)
AR (1) AR066677A1 (es)
AU (1) AU2008252931B2 (es)
BR (1) BRPI0811904A2 (es)
CA (1) CA2683935C (es)
CL (1) CL2008001509A1 (es)
CO (1) CO6241097A2 (es)
CR (1) CR11078A (es)
CU (1) CU24028B1 (es)
DK (1) DK2164473T3 (es)
DO (1) DOP2009000262A (es)
EA (1) EA018203B1 (es)
EC (1) ECSP099793A (es)
ES (1) ES2761227T3 (es)
GE (1) GEP20125582B (es)
GT (1) GT200900302A (es)
HN (1) HN2009003296A (es)
HU (1) HUE046490T2 (es)
IL (1) IL201571B (es)
MA (1) MA31445B1 (es)
ME (1) ME00955B (es)
MX (1) MX2009012536A (es)
MY (1) MY148915A (es)
NI (1) NI200900207A (es)
NZ (1) NZ580589A (es)
PA (1) PA8781501A1 (es)
PE (1) PE20090387A1 (es)
PL (1) PL2164473T3 (es)
PT (1) PT2164473T (es)
SI (1) SI2164473T1 (es)
SM (1) SMP200900099B (es)
SV (1) SV2009003421A (es)
TN (1) TN2009000447A1 (es)
TW (1) TWI412373B (es)
UA (1) UA97396C2 (es)
UY (1) UY31103A1 (es)
WO (1) WO2008142153A1 (es)
ZA (1) ZA200907168B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
ES2749864T3 (es) 2011-04-25 2020-03-24 Shan Dong Luye Pharm Co Ltd Composición de risperidona de microesferas de liberación controlada
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
US10821200B2 (en) 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
EP3339372A1 (en) * 2016-12-22 2018-06-27 Solvay SA Glycolic acid polymer composition
CN110870853B (zh) * 2018-08-29 2020-12-11 深圳翰宇药业股份有限公司 缓释帕瑞肽微球及其制备方法
MX2021006601A (es) * 2018-12-04 2021-07-07 Vanda Pharmaceuticals Inc Administracion de iloperidona de liberacion lenta.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
FI106926B (fi) * 1989-07-07 2001-05-15 Novartis Ag Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CA2316052C (en) * 1989-07-07 2008-09-02 David Bodmer Sustained release formulations of water soluble peptides
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
WO2005053732A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment

Also Published As

Publication number Publication date
DOP2009000262A (es) 2010-10-15
ZA200907168B (en) 2010-07-28
JP5507447B2 (ja) 2014-05-28
KR101930588B1 (ko) 2018-12-18
CN101677965B (zh) 2015-09-09
EA018203B1 (ru) 2013-06-28
UY31103A1 (es) 2009-01-05
EP2164473A1 (en) 2010-03-24
TWI412373B (zh) 2013-10-21
CR11078A (es) 2009-12-04
DK2164473T3 (da) 2019-12-16
IL201571A0 (en) 2010-05-31
EA200901523A1 (ru) 2010-04-30
MX2009012536A (es) 2009-12-03
CU24028B1 (es) 2014-10-02
SMP200900099B (it) 2010-11-12
PA8781501A1 (es) 2008-12-18
MY148915A (en) 2013-06-14
ME00955B (me) 2012-06-20
EP3666263A1 (en) 2020-06-17
GT200900302A (es) 2011-07-01
TW200906437A (en) 2009-02-16
PE20090387A1 (es) 2009-04-28
AU2008252931A1 (en) 2008-11-27
AR066677A1 (es) 2009-09-02
NI200900207A (es) 2010-09-07
KR20160002937A (ko) 2016-01-08
NZ580589A (en) 2011-12-22
US20130129798A1 (en) 2013-05-23
MA31445B1 (fr) 2010-06-01
TN2009000447A1 (en) 2011-03-31
WO2008142153A1 (en) 2008-11-27
CN101677965A (zh) 2010-03-24
CA2683935C (en) 2016-07-19
HN2009003296A (es) 2014-02-10
ES2761227T3 (es) 2020-05-19
PL2164473T3 (pl) 2020-07-27
GEP20125582B (en) 2012-07-25
US20100178344A1 (en) 2010-07-15
IL201571B (en) 2018-11-29
JP2010527971A (ja) 2010-08-19
CL2008001509A1 (es) 2009-05-08
CO6241097A2 (es) 2011-01-20
EP2164473B1 (en) 2019-09-11
PT2164473T (pt) 2019-12-11
SI2164473T1 (sl) 2020-02-28
AU2008252931B2 (en) 2011-09-01
SMAP200900099A (it) 2010-01-19
KR20100017904A (ko) 2010-02-16
CU20090200A7 (es) 2011-09-21
ECSP099793A (es) 2010-01-29
HUE046490T2 (hu) 2020-03-30
US9351923B2 (en) 2016-05-31
CA2683935A1 (en) 2008-11-27
UA97396C2 (ru) 2012-02-10
BRPI0811904A2 (pt) 2014-11-18

Similar Documents

Publication Publication Date Title
SV2009003421A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
IL202103A0 (en) Controlled release pharmaceutical compositions for prolonged effect
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BRPI0909820A2 (pt) Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
HN2011003195A (es) Modulares de gpr 119
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
BR112015011430A2 (pt) composição para liberação imediata e prolongada
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
HRP20181854T1 (hr) Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
BRPI0903914A2 (pt) Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
BRPI0812000A2 (pt) Métodos e composições para administração de oxibutinina
GT200800254A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion.
CL2008000550A1 (es) Compuestos derivados de pirazol-3-carboxamida en forma amorfa; disolucion solida amorfa; procedimiento de preparacion de la disolucion solida amorfa; y composicion farmaceutica que la comprende.